ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...
Please provide your email address to receive an email when new articles are posted on . The FDA has cleared an investigational new drug application for an epigenetic regulator to treat intractable ...
—This cross-sectional study investigated a possible association between a high GI symptom burden in types 1 and 2 diabetes with the presence of various neuropathies. A high gastrointestinal (GI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results